Últimas noticias sobre  (OTC:MRONS) Bolsa

WIIM

Unisys shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY25 sales guidance.

JP Morgan analyst Doug Anmuth maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $610 to $675.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Meta Platforms, Raises Price Target to $675

TTMI

TTM Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.

Peoples Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIS#NASDAQ">PFIS</a>) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $1.32 by 14.39 percent. This is a 174.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $45.80 million which beat the analyst consensus estimate of $44.30 million by 3.40 percent. This is a 101.60 percent increase over sales of $22.72 million the same period last year.

Earnings

Earnings Beats

PFIS

Peoples Financial Servs Q1 Adj. EPS $1.51 Beats $1.32 Estimate, Sales $45.80M Beat $44.30M Estimate

Baird analyst Mircea Dobre upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Underperform to Neutral and raises the price target from $300 to $309.

Upgrades

Baird Upgrades Caterpillar to Neutral, Raises Price Target to $309

Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>), a global leader in electric vehicle (EV) charging and energy management solutions, today announced a new partnership with Nissan Canada to launch a nationwide integrated home charging solution for Nissan electric vehicle owners.
As part of this program, RocketEV, one of Canada's leading EV charger installers, will provide professional installation services, helping deliver a seamless, one-stop shop experience for both new and existing Nissan EV drivers. The program is designed to simplify the home charging journey and make it more accessible to a broader audience.
Starting in May, Nissan EV owners across Canada will be able to purchase Wallbox's Pulsar Plus home charger and schedule installation through their local Nissan dealer or directly via the Nissan Canada website. This end-to-end solution offers a convenient, turnkey experience for EV drivers looking to charge at home with confidence.
"Our goal is to make home charging effortless and accessible for every EV driver," said Douglas Alfaro, Chief Business Development Officer at Wallbox. "Together with Nissan, we're helping shape a future where owning an electric vehicle is simpler, smarter, and more connected to people's everyday lives."
Pulsar Plus is Wallbox's best-selling home charger, trusted by drivers around the world for its speed, reliability, and sleek, compact design. It's designed to fit seamlessly into a variety of residential settings, including single-family homes, apartment buildings, and other multi-unit dwellings.
"As we continue our efforts to make EVs more accessible, this new partnership with Wallbox and RocketEV allows us to offer a simple solution for EV owners looking to install a home charger," said Andrew Harkness, Director of Dealer Network Development, Electrification and Corporate Strategy at Nissan Canada Inc. "The initiative will make it easier and more convenient for more consumers to switch to EVs."
This collaboration reflects a shared commitment to accelerating the transition to electric mobility in Canada. By combining Wallbox's cutting-edge charging technology, Nissan's legacy in EV innovation, and RocketEV's installation expertise, the initiative aims to remove barriers and deliver a more seamless ownership experience for current and future EV drivers.

Contracts

NSANY

Wallbox And Nissan Canada Enters Nationwide Home EV Charging Partnership

Gannett Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.03) by 200 percent. This is a 65.38 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $571.57 million which missed the analyst consensus estimate of $593.10 million by 3.63 percent. This is a 10.10 percent decrease over sales of $635.76 million the same period last year.

Earnings Misses

Gannett Co Q1 Adj. EPS $(0.09) Misses $(0.03) Estimate, Sales $571.57M Miss $593.10M Estimate

PodcastOne shares are trading higher. The company provided FY25 guidance.

Blue Owl Capital shares are trading lower after the company reported mixed Q1 financial results.

Baird analyst Andrew Wittmann downgrades Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Outperform to Neutral and lowers the price target from $72 to $69.

Downgrades

Baird Downgrades Parsons to Neutral, Lowers Price Target to $69

Our guests can soon book nonstop flights on Philippine Airlines from Honolulu and our&nbsp;West Coast hubs to Manila at alaskaair.com, plus earn and redeem Mileage Plan miles&nbsp;
&nbsp;Alaska Airlines is celebrating the addition of our newest global airline partner, Philippine Airlines, the flag carrier of the Philippines and the oldest operating commercial airline in Asia. With our new frequent flyer partnership, Alaska becomes Philippine Airlines' first loyalty partner in North America, opening the door for our guests to book travel to exotic, once-in-a-lifetime destinations such as Palawan and Boracay in the Philippines.
In the coming months, our guests will be able to book flights on Philippine Airlines directly at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417598-1&amp;h=2805840937&amp;u=https%3A%2F%2Fwww.alaskaair.com%2F&amp;a=alaskaair.com">alaskaair.com</a>, earn Mileage Plan miles for their travel and redeem Mileage Plan miles for Philippine Airlines flights.
Philippine Airlines offers a variety of flight options between Alaska's hubs in Honolulu and the West Coast to Manila: Five nonstop flights a week from Honolulu; three nonstops a week from Seattle; two daily nonstops from Los Angeles; and a daily nonstop from San Francisco. From Philippine Airlines' hub in Manila, travelers can connect to dozens of additional destinations in Asia and elsewhere.
"Philippine Airlines is a terrific addition to our roster of global airlines offering world-class service and amenities," said Brett Catlin, vice president of loyalty, alliances and sales at Alaska Airlines. "We're excited to make this announcement as we mark the beginning of Asian American, Native Hawaiian and Pacific Islander Heritage Month. The large Filipino communities living in Hawaii, California and Washington state can travel on Philippine Airlines long-haul, widebody aircraft and soon earn valuable Mileage Plan miles on their transpacific journeys."
This new partnership builds on the existing one that Hawaiian Airlines already had in place with Philippine Airlines. With the combination of Alaska and Hawaiian, we're delivering more for our guests, including improvements and expansions to the partnership between Hawaiian and Philippine Airlines. In addition to Philippine Airlines continuing to offer Hawaiian codeshare flights on its website, Hawaiian flyers will soon be able to earn and redeem miles on Philippine Airlines when they use their Mileage Plan number.

Alaska Airlines Announces Addition Of Philippine Airlines As Newest Global Partner

JP Morgan analyst Harlan Sur upgrades Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) from Neutral to Overweight and raises the price target from $45 to $57.

JP Morgan Upgrades Western Digital to Overweight, Raises Price Target to $57

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54247032&amp;newsitemid=20250501757779&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2011f6b50e7acc8c3e5f684784e7f7e3">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart's potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma &amp; Immunology.
Overview of results from the Phase 1a trial of navenibart in healthy subjects:
<ul>
<li>For all doses ≥300 mg, navenibart mean half-life ranged from 82 to 105 days, supporting the potential for administration every 3 and 6 months. Navenibart's inhibition of plasma kallikrein activity versus placebo was statistically significant (P&lt;0.05).</li>
<li>Navenibart was well-tolerated, with similar rates of adverse events between navenibart and placebo, and no serious adverse events were observed.</li>
<li>Results demonstrated early proof of concept for navenibart as a potential long-acting therapy for HAE.</li>
</ul>

ATXS

Astria Therapeutics Publishes Navenibart Phase 1a Healthy Subject Results In Annals of Allergy, Asthma & Immunology

TRNR

Interactive Strength shares are trading higher. The company provided a shareholder update on developments and acquisitions for the year.

Agnico Eagle Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AEM#TSX">AEM</a>)&nbsp;("Agnico Eagle") announced today that further to its news release dated April 24, 2025, it has received approval from the Toronto Stock Exchange (the "TSX") of Agnico Eagle's notice of intention to renew its normal course issuer bid (the "NCIB").
Under the NCIB, Agnico Eagle may purchase for cancellation, on the open market at its discretion, during the period commencing on May 4, 2025 and ending on the earlier of May 3, 2026 and the completion of purchases under the NCIB, up to the lesser of: (i) 25,174,240 common shares of Agnico Eagle ("Common Shares"), which is 5% of the issued and outstanding Common Shares; and (ii) that number of Common Shares that can be purchased by Agnico Eagle under the NCIB for an aggregate purchase price, excluding commissions, of not more than $1,000,000,000, subject to the normal terms and limitations of such bids. Based on the closing share price of $119.02 on April 28, 2025, 8,401,949 Common Shares would be purchasable under the NCIB, representing approximately 1.67% of the issued and outstanding Common Shares as of April 28, 2025. As of April 28, 2025, Agnico Eagle had 503,484,810&nbsp;issued and outstanding Common Shares.

Buybacks

TSX:AEM

Agnico Eagle Announces Renewal Of Normal Course Issuer Bid Of Up To 25,174,240 Common Shares, Which Is 5% Of The Issued And Outstanding Common Shares

Guidance

Gannett Reaffirmed FY25 Guidance For Total Revenues To Be Down In The Low Single Digits On A Same Store Basis

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting).
Without treatment, 1 in 10 patients experiencing symptoms of severe AS may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredictably.
"There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend ‘watchful waiting' until symptoms develop," said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. "As we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became symptomatic in sudden and unpredictable ways, underscoring the importance of early evaluation by a heart team to improve patient outcomes and benefit the healthcare system."

Biotech

General

Edwards Announces TAVR Receives FDA Approval For Patients With Asymptomatic Severe Aortic Stenosis

VSEC

VSE Corporation Acquires Turbine Weld Industries For ~$50M In Cash

JP Morgan analyst Jeffrey Zekauskas upgrades Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) from Neutral to Overweight and maintains the price target from $57 to $57.

SLGN

JP Morgan Upgrades Silgan Hldgs to Overweight, Maintains Price Target to $57

CTSH

Cognizant Technology Solutions shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance with its midpoint above estimates.

Liability Co Int Cl A Shares Of Beneficial Interest

Comments

Noticias

Últimas noticias sobre (OTC:MRONS) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL